Literature DB >> 21248070

Genome-wide analysis of alternative splicing in medulloblastoma identifies splicing patterns characteristic of normal cerebellar development.

Francesca Menghi1, Thomas S Jacques, Martino Barenco, Ed C Schwalbe, Steven C Clifford, Mike Hubank, Jonathan Ham.   

Abstract

Alternative splicing is an important mechanism for the generation of protein diversity at a post-transcriptional level. Modifications in the splicing patterns of several genes have been shown to contribute to the malignant transformation of different tissue types. In this study, we used the Affymetrix Exon arrays to investigate patterns of differential splicing between pediatric medulloblastomas and normal cerebellum on a genome-wide scale. Of the 1,262 genes identified as potentially generating tumor-associated splice forms, we selected 14 examples of differential splicing of known cassette exons and successfully validated 11 of them by reverse transcriptase PCR. The pattern of differential splicing of three validated events was characteristic for the molecular subset of sonic hedgehog (Shh)-driven medulloblastomas, suggesting that their unique gene signature includes the expression of distinctive transcript variants. Generally, we observed that tumor and normal fetal cerebellar samples shared significantly lower exon inclusion rates than normal adult cerebellum. We investigated whether tumor-associated splice forms were expressed in primary cultures of Shh-dependent mouse cerebellar granule cell precursors (GCP) and found that Shh caused a decrease in the cassette exon inclusion rate of five of the seven tested genes. Furthermore, we observed a significant increase in exon inclusion between postnatal days 7 and 14 of mouse cerebellar development, at the time when GCPs mature into postmitotic neurons. We conclude that inappropriate splicing frequently occurs in human medulloblastomas and may be linked to the activation of developmental signaling pathways and a failure of cerebellar precursor cells to differentiate. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248070      PMCID: PMC3060131          DOI: 10.1158/0008-5472.CAN-10-2519

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  Detection of the tight junction-associated protein ZO-1 in astrocytes and other nonepithelial cell types.

Authors:  A G Howarth; M R Hughes; B R Stevenson
Journal:  Am J Physiol       Date:  1992-02

2.  Nova-1 regulates neuron-specific alternative splicing and is essential for neuronal viability.

Authors:  K B Jensen; B K Dredge; G Stefani; R Zhong; R J Buckanovich; H J Okano; Y Y Yang; R B Darnell
Journal:  Neuron       Date:  2000-02       Impact factor: 17.173

3.  Differential expression of survivin splice isoforms in medulloblastomas.

Authors:  X-N Li; Q Shu; J M Su; A M Adesina; K K Wong; L Perlaky; B A Antalffy; S M Blaney; C C Lau
Journal:  Neuropathol Appl Neurobiol       Date:  2007-02       Impact factor: 8.090

4.  Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays.

Authors:  Pim J French; Justine Peeters; Sebastiaan Horsman; Elza Duijm; Ivar Siccama; Martin J van den Bent; Theo M Luider; Johan M Kros; Peter van der Spek; Peter A Sillevis Smitt
Journal:  Cancer Res       Date:  2007-06-15       Impact factor: 12.701

5.  Crystal structure of human DAAM1 formin homology 2 domain.

Authors:  Masami Yamashita; Tomohito Higashi; Shiro Suetsugu; Yusuke Sato; Tomoyuki Ikeda; Ryutaro Shirakawa; Toru Kita; Tadaomi Takenawa; Hisanori Horiuchi; Shuya Fukai; Osamu Nureki
Journal:  Genes Cells       Date:  2007-11       Impact factor: 1.891

6.  An RNAi screen of chromatin proteins identifies Tip60-p400 as a regulator of embryonic stem cell identity.

Authors:  Thomas G Fazzio; Jason T Huff; Barbara Panning
Journal:  Cell       Date:  2008-07-11       Impact factor: 41.582

7.  Regulation of vertebrate nervous system alternative splicing and development by an SR-related protein.

Authors:  John A Calarco; Simone Superina; Dave O'Hanlon; Mathieu Gabut; Bushra Raj; Qun Pan; Ursula Skalska; Laura Clarke; Danielle Gelinas; Derek van der Kooy; Mei Zhen; Brian Ciruna; Benjamin J Blencowe
Journal:  Cell       Date:  2009-09-04       Impact factor: 41.582

8.  Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: childhood cancer survivor study.

Authors:  Roger J Packer; James G Gurney; Judy A Punyko; Sarah S Donaldson; Peter D Inskip; Marilyn Stovall; Yutaka Yasui; Ann C Mertens; Charles A Sklar; H Stacy Nicholson; Lonnie K Zeltzer; Joseph P Neglia; Leslie L Robison
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 50.717

9.  X:Map: annotation and visualization of genome structure for Affymetrix exon array analysis.

Authors:  Tim Yates; Michał J Okoniewski; Crispin J Miller
Journal:  Nucleic Acids Res       Date:  2007-10-11       Impact factor: 16.971

10.  Developmental expression and differentiation-related neuron-specific splicing of metastasis suppressor 1 (Mtss1) in normal and transformed cerebellar cells.

Authors:  Alexander Glassmann; Sabine Molly; Lachezar Surchev; Tommy A Nazwar; Martin Holst; Wolfgang Hartmann; Stephan L Baader; John Oberdick; Torsten Pietsch; Karl Schilling
Journal:  BMC Dev Biol       Date:  2007-10-09       Impact factor: 1.978

View more
  10 in total

1.  Most expression and splicing changes in myotonic dystrophy type 1 and type 2 skeletal muscle are shared with other muscular dystrophies.

Authors:  Linda L Bachinski; Keith A Baggerly; Valerie L Neubauer; Tamara J Nixon; Olayinka Raheem; Mario Sirito; Anna K Unruh; Jiexin Zhang; Lalitha Nagarajan; Lubov T Timchenko; Guillaume Bassez; Bruno Eymard; Josep Gamez; Tetsuo Ashizawa; Jerry R Mendell; Bjarne Udd; Ralf Krahe
Journal:  Neuromuscul Disord       Date:  2013-11-15       Impact factor: 4.296

2.  Aberrant cAMP metabolism in NF1 malignant peripheral nerve sheath tumor cells.

Authors:  Ian Dang; George H De Vries
Journal:  Neurochem Res       Date:  2011-03-05       Impact factor: 3.996

3.  Subgroup-specific alternative splicing in medulloblastoma.

Authors:  Adrian M Dubuc; A Sorana Morrissy; Nanne K Kloosterhof; Paul A Northcott; Emily Py Yu; David Shih; John Peacock; Wieslawa Grajkowska; Timothy van Meter; Charles G Eberhart; Stefan Pfister; Marco A Marra; William A Weiss; Stephen W Scherer; James T Rutka; Pim J French; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2012-02-23       Impact factor: 17.088

4.  Genome-wide analysis of alternative transcripts in human breast cancer.

Authors:  Ji Wen; Kevin H Toomer; Zhibin Chen; Xiaodong Cai
Journal:  Breast Cancer Res Treat       Date:  2015-04-26       Impact factor: 4.872

Review 5.  The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.

Authors:  Thomas R Webb; Amanda S Joyner; Philip M Potter
Journal:  Drug Discov Today       Date:  2012-08-03       Impact factor: 7.851

6.  Splicing programs and cancer.

Authors:  Sophie Germann; Lise Gratadou; Martin Dutertre; Didier Auboeuf
Journal:  J Nucleic Acids       Date:  2011-10-24

Review 7.  Non-Canonical Splicing and Its Implications in Brain Physiology and Cancer.

Authors:  Consuelo Pitolli; Alberto Marini; Claudio Sette; Vittoria Pagliarini
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

8.  Exon-level expression analyses identify MYCN and NTRK1 as major determinants of alternative exon usage and robustly predict primary neuroblastoma outcome.

Authors:  A Schramm; B Schowe; K Fielitz; M Heilmann; M Martin; T Marschall; J Köster; J Vandesompele; J Vermeulen; K de Preter; J Koster; R Versteeg; R Noguera; F Speleman; S Rahmann; A Eggert; K Morik; J H Schulte
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

Review 9.  An emerging role for long non-coding RNAs in cancer metastasis.

Authors:  Jason T Serviss; Per Johnsson; Dan Grandér
Journal:  Front Genet       Date:  2014-07-18       Impact factor: 4.599

10.  Expression profile-based screening for critical genes reveals S100A4, ACKR3 and CDH1 in docetaxel-resistant prostate cancer cells.

Authors:  Sha Zhu; Zhixue Min; Xianli Qiao; Shengxian Chen; Jian Yang; Xiao Zhang; Xigang Liu; Weijie Ran; Renguang Lv; Ying Lin; Jin Wang
Journal:  Aging (Albany NY)       Date:  2019-12-29       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.